Nektar Therapeutics (NKTR) Net Cash Flow (2010 - 2026)

Nektar Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at $134.5 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 2610.02% year-over-year to $134.5 million; the TTM figure through Mar 2026 stood at $110.7 million (up 1235.03% YoY), while the FY2025 annual figure was -$29.1 million, down 424.56% from the prior year.
• Net Cash Flow was $134.5 million for Q1 2026 at Nektar Therapeutics, up from -$25.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $134.5 million in Q1 2026 to a low of -$29.7 million in Q4 2023.
• Historically, Net Cash Flow has averaged $7.3 million across 5 years, with a median of $2.2 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Net Cash Flow sank 373.69% in 2023, then surged 2610.02% in 2026.
• A 5-year view of Net Cash Flow shows it stood at -$17.6 million in 2022, then sank by 68.61% to -$29.7 million in 2023, then jumped by 147.59% to $14.1 million in 2024, then sank by 283.67% to -$25.9 million in 2025, then surged by 618.84% to $134.5 million in 2026.
• The last three Net Cash Flow figures came in at $134.5 million (Q1 2026), -$25.9 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.